Late-diabetic complications, inflammatory bowel disease (IBD), kidney disease, and previous falls (binary variables) were identified through diagnosis codes
For weight management, some patients may attempt discontinuation after achieving goals, though most will require ongoing treatment to maintain weight loss
A systematic review and meta-regression published in eClinicalMedicine (November 2025) confirmed what a lot of GLP-1 users have experienced firsthand: weight, HbA1c, and blood pressure all rebounded after stopping GLP-1 therapy
This guide explores how your skin makes pigment, how glutathione and vitamin C fit into that process, and what you need to know before considering any kind of infusion
A new, federally funded retrospective study led by Johns Hopkins Medicine strongly suggests that semaglutide and other GLP-1 RAs did not statistically change the risk of developing neovascular age-related macular degeneration (NVAMD) a fast-progressing, blinding condition that is caused by uncontrolled, abnormal blood vessel growth in the back of the eye in adults with type 2 diabetes without a prior history of GLP-1 use